CD155在恶性肿瘤中的免疫调控作用研究进展

doi:10.3969/j.issn.1001-8131.2023.02.047

Abstract
Figure/Table
References
Related Citation (3)

Download: PDF (487 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract CD155,a glycoprotein of immunoglobulin superfamily,is up-regulated in a variety of malignant tumor cells and associated with patient prognosis.Recently,the immunoregulatory role of CD155 has attracted extensive attention in tumors.CD155 could interact with co-stimulatory receptors（CD226）and co-inhibitory receptors（TIGIT and CD96）,regulating function of tumor infiltrating lymphocytes.Immunotherapy of targeting CD155 signaling is expected to improve the prognosis of tumor patients and has great potential for clinical application.This article will review the research progress of CD155 from the aspects of the relationship between CD155 and the prognosis of malignant tumor patients,immunoregulatory role and related immunotherapy.

Key words： CD155 CD226 TIGIT CD96 malignant tumors immunotherapy

Received: 06 May 2022

PACS:

R730.4

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Liu Xue
	Guo Lingchuan

Cite this article:

Liu Xue,Guo Lingchuan. Research Progress on the Immunoregulatory Role of CD155 in Malignant Tumors[J]. journal1, 2023, 43(2): 127-129.

URL:

http://www.hrbyybjb.org.cn/EN/10.3969/j.issn.1001-8131.2023.02.047 OR http://www.hrbyybjb.org.cn/EN/Y2023/V43/I2/127

[1] Bowers JR,Readler JM,Sharma P,et al.Poliovirus Receptor:More than a simple viral receptor[J].Virus research.2017;242:1-6.
[2] Sun Y,Luo J,Chen Y,et al.Combined evaluation of the expression status of CD155 and TIGIT plays an important role in the prognosis of LUAD(lung adenocarcinoma)[J].Internationalimmunopharmacology.2020;80:106198.
[3] Li YC,Zhou Q,Song QK,et al.Overexpression of an Immune Checkpoint(CD155)in Breast Cancer Associated with Prognostic Significance and Exhausted Tumor-Infiltrating Lymphocytes:A Cohort Study[J].Journal of immunology research.2020;2020:3948928.
[4] Yong H,Cheng R,Li X,et al.CD155 expression and its prognostic value in postoperative patients with breast cancer[J].Biomedicine & pharmacotherapy= Biomedecine & pharmacotherapie.2019;115:108884.
[5] Liu L,Wang Y,Geng C,et al.CD155 Promotes the Progression of Cervical Cancer Cells Through AKT/mTOR and NF-κB Pathways[J].Frontiers in oncology.2021;11:655302.
[6] Mori K,Matsumoto K,Amano N,et al.Expression of Membranous CD155 Is Associated with Aggressive Phenotypes and a Poor Prognosis in Patients with Bladder Cancer[J].Cancers.2022;14(6).
[7] Lepletier A,Madore J,O'Donnell JS,et al.Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma[J].Clinical cancer research :an official journal of the American Association for Cancer Research.2020;26(14):3671-81.
[8] Lim SM,Hong MH,Ha SJ,et al.Overexpression of poliovirus receptor is associated with poor prognosis in head and neck squamous cell carcinoma patients[J].Journal of cancer research and clinical oncology.2021;147(9):2741-50.
[9] Lee JB,Hong MH,Park SY,et al.Overexpression of PVR and PD-L1 and its association with prognosis in surgically resected squamous cell lung carcinoma[J].Scientific reports.2021;11(1):8551.
[10] Xu Y,Cui G,Jiang Z,et al.Survival analysis with regard to PD-L1 and CD155 expression in human small cell lung cancer and a comparison with associated receptors[J].Oncology letters.2019;17(3):2960-8.
[11] Jiang C,Qu X,Ma L,et al.CD155 expression impairs anti-PD1 therapy response in non-small cell lung cancer[J].Clinical and experimental immunology.2022.
[12] Qu P,Huang X,Zhou X,et al.Loss of CD155 expression predicts poor prognosis in hepatocellular carcinoma[J].Histopathology.2015;66(5):706-14.
[13] Triki H,Charfi S,Bouzidi L,et al.CD155 expression in human breast cancer:Clinical significance and relevance to natural killer cell infiltration[J].Life sciences.2019;231:116543.
[14] Sayitoglu EC,Georgoudaki AM,Chrobok M,et al.Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D[J].Frontiers in immunology.2020;11:40.
[15] Weulersse M,Asrir A,Pichler AC,et al.Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8(+)T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy[J].Immunity.2020;53(4):824-39.e10.
[16] Nakamura-Shinya Y,Iguchi-Manaka A,Murata R,et al.DNAM-1 promotes inflammation-driven tumor development via enhancing IFN-γ production[J].International immunology.2022;34(3):149-57.
[17] Okumura G,Iguchi-Manaka A,Murata R,et al.Tumor-derived soluble CD155 inhibits DNAM-1-mediated antitumor activity of natural killer cells[J].The Journal of experimental medicine.2020;217(4):1.
[18] Zhang C,Wang Y,Xun X,et al.TIGIT Can Exert Immunosuppressive Effects on CD8+ T Cells by the CD155/TIGIT Signaling Pathway for Hepatocellular Carcinoma In Vitro[J].Journal of immunotherapy(Ha-gerstown,Md :1997).2020;43(8):236-43.
[19] Li S,Ding J,Wang Y,et al.CD155/TIGIT signaling regulates the effector function of tumor-infiltrating CD8+ T cell by NF-κB pathway in colorectal cancer[J].Journal of gastroenterology and hepatology.2022;37(1):154-63.
[20] Maas RJ,Hoogstad-van Evert JS,Van der Meer JM,et al.TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer[J].Oncoimmunology.2020;9(1):1843247.
[21] Zhang H,Liu Q,Lei Y,et al.Direct interaction between CD155 and CD96 promotes immunosuppression in lung adenocarcinoma[J].Cellular & molecular immunology.2021;18(6):1575-7.
[22] Zhuo B,Li Y,Gu F,et al.Overexpression of CD155 relates to metastasis and invasion in osteosarcoma[J].Oncology letters.2018;15(5):7312-8.
[23] Wang Y,Luo YL,Chen YF,et al.Dually regulating the proliferation and the immune microenvironment of melanoma via nanoparticle-delivered siRNA targeting onco-immunologic CD155[J].Biomaterials science.2020;8(23):6683-94.
[24] Jeong BS,Nam H,Lee J,et al.Structural and functional characterization of a monoclonal antibody blocking TIGIT[J].mAbs.2022;14(1):2013750.
[25] Mao L,Xiao Y,Yang QC,et al.TIGIT/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells[J].Oral oncology.2021;121:105472.
[26] Barsoumian HB,Sezen D,Menon H,et al.High Plus Low Dose Radiation Strategy in Combination with TIGIT and PD1 Blockade to Promote Systemic Antitumor Responses[J].Cancers.2022;14(1).
[27] Niu J,Maurice-Dror C,Lee DH,et al.First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors,including non-small-cell lung cancer(☆)[J].Annals of oncology :official journal of the European Society for Medical Oncology.2022;33(2):169-80.
[28] Mittal D,Lepletier A,Madore J,et al.CD96 Is an Immune Checkpoint That Regulates CD8(+)T-cell Antitumor Function[J].Cancer immunology research.2019;7(4):559-71.
[29] Brown MC,Holl EK,Boczkowski D,et al.Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs[J].Science translational medicine.2017;9(408).
[30] Beasley GM,Nair SK,Farrow NE,et al.Phase I trial of intratumoral PVSRIPO in patients with unresectable,treatment-refractory melanoma[J].Journal for immuno-therapy of cancer.2021;9(4).